Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Also available conjugated with Biotin.
Western blot (0.1 - 0.2 µg/ml)
ELISA (0.5 - 2 µg/ml)
(applications tested for the base form of this product only)
E.coli derived recombinant Murine MIP-2.
Neutralization: To yield one-half maximal inhibition [ND50] of the biological activity of Murine MIP-2 (15.0 ng/ml), a concentration of 0.52-0.9 ug/ml of this antibody is required. Sandwich ELISA: To detect Murine MIP-2 by sandwich ELISA (using 100 ul/well antibody solution) a concentration of 0.5-2.0 ug/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with LifeSpan's Biotinylated Anti-Murine MIP-2 (LS-C104503) as a detection antibody, allows the detection of at least 0.2-0.4 ng/well of recombinant Murine MIP-2. Western Blot: To detect Murine MIP-2 by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 ug/ml. When used in conjunction with compatible secondary reagents the detection limit for recombinant Murine MIP-2 is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.
Lyophilized from PBS, pH 7.2
Store Lyophilized at room temperature up to 1 month; Reconstituted for up to 2 weeks at 2°C to 8°C. Aliquot and freeze at -20°C for long term storage. Avoid freeze/thaw cycles.
Produced by activated monocytes and neutrophils and expressed at sites of inflammation. Hematoregulatory chemokine, which, in vitro, suppresses hematopoietic progenitor cell proliferation. GRO-beta(5-73) shows a highly enhanced hematopoietic activity.